Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | MAOB | P27338 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | ACHE | P22303 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | CA12 | O43570 | 1/20 | 0.67 |
| ▸ | CA1 | P00915 | 1/20 | 0.67 |
| ▸ | CA2 | P00918 | 1/20 | 0.67 |
| ▸ | CA7 | P43166 | 1/20 | 0.67 |
| ▸ | CA9 | Q16790 | 1/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL252026 | 1.00 | HPGD (0.79) | HPGDALDH1A1USP2SIGMAR1BLM | |
| Hydrochloric Acid SCHEMBL1597472 | 0.98 | HPGD (0.76) | HPGDALDH1A1USP2SIGMAR1BLM | |
| SCHEMBL2614241 | 0.93 | HPGD (0.84) | HPGDALDH1A1USP2SIGMAR1BLM | |
| SCHEMBL1938606 | 0.93 | HPGD (0.70) | HPGDALDH1A1USP2SIGMAR1BLM | |
| SCHEMBL27989163 | 0.93 | ALDH1A1 (0.85) | HPGDALDH1A1USP2SIGMAR1BLM | |
| SCHEMBL4143492 | 0.91 | HPGD (0.68) | HPGDALDH1A1USP2SIGMAR1BLM | |
| SCHEMBL254870 | 0.91 | HPGD (0.96) | HPGDALDH1A1USP2SIGMAR1BLM | |
| SCHEMBL18228404 | 0.91 | HPGD (0.96) | HPGDALDH1A1USP2SIGMAR1BLM | |
| SCHEMBL1263133 | 0.91 | HPGD (0.88) | HPGDALDH1A1USP2SIGMAR1BLM | |
| SCHEMBL9410748 | 0.89 | HPGD (0.66) | HPGDALDH1A1USP2SIGMAR1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6527384-B2 | Decolorizable ink composition and ink jet printer using the ink composition | RICOH COMPANY, LTD. (JP) | 2003-03-04 | — | — | US | claimed |
| US-4072712-A | FROM ISOCYANATES, CATALYSIS | BAYER AKTIENGESELLSCHAFT (DT) | 1978-02-07 | — | — | US | claimed |
| US-11643691-B2 | Predictive biomarkers for cancer immunotherapy and methods of using same | DUKE UNIVERSITY (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2023077057-A1 | SMALL-MOLECULAR INHIBITORS FOR THE BETA-CATENIN/ B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230108479-A1 | Substituted N-Benzhydrylacetamide Inhibitors of Jamanji Domain Histone Demethylases for the Treatment of Cancer | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2023-04-06 | — | — | US | disclosed |
| US-11568956-B2 | Methods for identifying inhibitors of amyloid protein aggregation | TREVENTIS CORPORATION (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220364184-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF A POOR PROGNOSIS SUBTYPE OF COLORECTAL CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| US-20210380558-A1 | BETA-CATENIN AND B-CELL LYMPHOMA 9 (BCL9) INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20210340123-A1 | BETA-CATENIN AND B-CELL LYMPHOMA 9 (BCL9) INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-11-04 | — | — | US | disclosed |
| WO-2021178721-A1 | SUBSTITUTED N-BENZHYDRYLACETAMIDE INHIBITORS OF JUMANJI DOMAIN HISTONE DEMETHYLASES FOR THE TREATMENT OF CANCER | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2021-09-10 | — | — | WO | disclosed |
| WO-2020081917-A1 | ΒETA-CATENIN AND B-CELL LYMPHOMA 9 (BCL9) INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| EP-1149877-B1 | Decolorizable ink composition and ink jet printer using the ink composition | RICOH KK (JP) | 2003-06-11 | — | — | EP | disclosed |
| US-6527384-B2 | Decolorizable ink composition and ink jet printer using the ink composition | RICOH COMPANY, LTD. (JP) | 2003-03-04 | — | — | US | disclosed |
| US-20020175982-A1 | Decolorizable ink composition and ink jet printer using the ink composition | RICOH COMPANY, LTD. (JP) | 2002-11-28 | — | — | US | disclosed |
| EP-1149877-A1 | Decolorizable ink composition and ink jet printer using the ink composition | Ricoh Company, Ltd. (JP) | 2001-10-31 | — | — | EP | disclosed |
| EP-0308978-B1 | MULTI-COLOR HEAT SENSITIVE RECORDING MATERIAL | KANZAKI PAPER MANUFACTURING CO., LTD. (JP) | 1993-04-07 | — | — | EP | disclosed |
| US-4906604-A | Multi-color heat sensitive recording material | KANZAKI PAPER MANUFACTURING CO., LTD. (JP) | 1990-03-06 | — | — | US | disclosed |
| EP-0308978-A2 | Multi-color heat sensitive recording material | KANZAKI PAPER MANUFACTURING CO., LTD. (JP) | 1989-03-29 | — | — | EP | disclosed |
| US-4663641-A | LEUCO DYES; DECOLORIZING AGENTS, PIPERAZINE COMPOUND; AMIDES AND TERTIARY AMINES | RICOH COMPANY, LTD. (JP) | 1987-05-05 | — | — | US | disclosed |
| US-4072712-A | FROM ISOCYANATES, CATALYSIS | BAYER AKTIENGESELLSCHAFT (DT) | 1978-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108479-A1 | Substituted N-Benzhydrylacetamide Inhibitors of Jamanji Domain Histone Demethylases for the Treatment of Cancer | KDM1B, KDM2A, KDM1A | HPGD 1293/4885ALDH1A1 1458/4885USP2 300/4885 |
| US-20210380558-A1 | BETA-CATENIN AND B-CELL LYMPHOMA 9 (BCL9) INHIBITORS | BCL9, BCL9L, CTNNB1 | HPGD 3202/4885ALDH1A1 2669/4885USP2 2461/4885 |
| US-20210340123-A1 | BETA-CATENIN AND B-CELL LYMPHOMA 9 (BCL9) INHIBITORS | BCL9, BCL9L, CTNNB1 | HPGD 3202/4885ALDH1A1 2669/4885USP2 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.